Li Yongji, Wu Zhannan, He Wei, Qin Chao, Yao Jing, Zhou Jianping, Yin Lifang
†State Key Laboratory of Natural Medicines and ‡Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China.
Mol Pharm. 2015 May 4;12(5):1485-500. doi: 10.1021/mp5008037. Epub 2015 Mar 31.
About 40% of the marketed drugs and 70-90% of new drug candidates are insoluble in water and therefore poorly bioavailable, which significantly compromises their therapeutic effects. A formulation of nanosuspensions achieved by reducing the pure drug particle size down to seb-micron range is one of the most promising approaches to overcome the insolubility. However, the nanosuspension formulations are subject to instability because of nucleation and particle growth. Therefore, a stabilizer is needed to be incorporated into the nanosuspension formulation during the preparation process to suppress the aggregation of drug particles. β-LG, a globular protein, is broken by heat-induced denaturation, and its hydrophobic area is exposed, which allows it to associate with organic particles. PTX, an insoluble drug, is widely used for the clinical treatment of human cancer. However, this drug's clinical application is greatly limited by intrinsic defects including poor solubility, adverse side effects, and poor tumor penetration. In this study, we prepared β-LG-stabilized PTX nanosuspensions (PTX-NS) by coating the protein onto nanoscaled drug particles, investigating the stabilization effect of β-LG on PTX-NS, and evaluating its in vitro and in vivo performance. PTX-NS with a diameter of approximately 200 nm was easily prepared. β-LG produced significantly stabilized effect on PTX-NS via the interaction between the hydrophobic area of the protein and the hydrophobic surface of the drug particles, which resulted in a conformational change of the protein, the loss of both secondary and tertiary structures, and the transition of Trp residues to a less hydrophobic condition. Importantly, unlike other conventional nanoparticles, PTX-NS could directly translocated across the membrane into the cytosol in an energy-independent manner, without entrapment within the endosomal-lysosomal system. Moreover, compared with Taxol, PTX-NS increased AUC and Cmax by 26- and 16-fold, respectively, and prolonged T1/2 by 314-fold. As expected, PTX-NS had better in vitro and in vivo antitumor activity compared to PTX alone. Additionally, β-LG is cyto- and bio-compatible, and PTX-NS is not toxic to healthy tissues. In conclusion, the present study has suggested the high potency of globular proteins, such as β-LG, as novel biomaterials for nanosuspension platform to improve the drug delivery for disease treatment.
市售药物中约40%以及70 - 90%的新药候选物都不溶于水,因此生物利用度差,这显著影响了它们的治疗效果。通过将纯药物粒径减小至亚微米范围而制备的纳米混悬液制剂是克服难溶性最有前景的方法之一。然而,纳米混悬液制剂由于成核和颗粒生长而存在稳定性问题。因此,在制备过程中需要加入稳定剂以抑制药物颗粒的聚集。β -乳球蛋白(β-LG)是一种球状蛋白,受热诱导变性后会被破坏,其疏水区域暴露,从而使其能够与有机颗粒结合。紫杉醇(PTX)是一种不溶性药物,广泛用于人类癌症的临床治疗。然而,这种药物的临床应用受到其固有缺陷的极大限制,包括溶解度差、副作用大以及肿瘤穿透性差。在本研究中,我们通过将蛋白质包被在纳米级药物颗粒上制备了β-LG稳定的PTX纳米混悬液(PTX-NS),研究了β-LG对PTX-NS的稳定作用,并评估了其体外和体内性能。直径约200 nm的PTX-NS很容易制备。β-LG通过蛋白质的疏水区域与药物颗粒的疏水表面之间的相互作用对PTX-NS产生了显著的稳定作用,这导致了蛋白质的构象变化,二级和三级结构的丧失,以及色氨酸残基向疏水性较低状态的转变。重要的是,与其他传统纳米颗粒不同,PTX-NS可以以能量非依赖的方式直接穿过细胞膜进入细胞质,而不会被困在内体 - 溶酶体系统中。此外,与紫杉醇相比,PTX-NS的AUC和Cmax分别增加了26倍和16倍,T1/2延长了314倍。正如预期的那样,与单独的PTX相比,PTX-NS具有更好的体外和体内抗肿瘤活性。此外,β-LG具有细胞和生物相容性,PTX-NS对健康组织无毒。总之,本研究表明球状蛋白如β-LG作为纳米混悬液平台的新型生物材料在改善疾病治疗的药物递送方面具有高效性。